Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study - PubMed (original) (raw)
Randomized Controlled Trial
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
Frederik Persson et al. Scand J Clin Lab Invest. 2008.
Abstract
Objective: To evaluate risk factors for progression from persistent microalbuminuria to diabetic nephropathy in the Irbesartan in Patients with Type 2 diabetes and Microalbuminuria (IRMA 2) study, including biomarkers of endothelial dysfunction, chronic low-grade inflammation, growth factors and advanced glycation end products (AGE peptides).
Methods: IRMA 2 was a 2-year multicentre, randomized, double-blind trial comparing irbesartan (150 and 300 mg once daily) versus placebo. The primary end-point was time to onset of diabetic nephropathy. Samples from a subgroup from the placebo and the 300 mg irbesartan treatment group were used in this post-hoc analysis (n = 269, 68 %). Nine biomarkers were analysed: high sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), fibrinogen, von Willebrand Factor (vWf), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular cell adhesion molecule-1 (sICAM-1), sE-selectin, transforming growth factor-beta (TGF-beta) and AGE peptides. Mean standard deviation scores (Z-scores) were used to combine biomarker information.
Results: In a Cox enter model with combined Z-scores for biomarkers of endothelial dysfunction (vWf, sVCAM-1, sICAM-1, sE-selectin) and for biomarkers of inflammation (hs-CRP, IL-6, fibrinogen), endothelial dysfunction (hazard ratio for a 28 % increase ( = 1 SD) in Z-score) 3.20 (1.56 to 6.56), p = 0.001) and UAER (HR for a 75 % increase ( = 1 SD) in UAER) 2.61 (1.30 to 5.23), p = 0.007) were found as independent predictors. Independently, IL-6 and vWf predicted the end-point. In addition, endothelial Z-score was associated with progression of albuminuria (p = 0.038).
Conclusion: Endothelial dysfunction and possibly inflammation are novel predictors of progression to diabetic nephropathy in patients with type 2 diabetes and microalbuminuria independently of traditional risk factors. ClinicalTrials.gov ID: NCT00317915.
Similar articles
- Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH. Persson F, et al. Diabetes. 2006 Dec;55(12):3550-5. doi: 10.2337/db06-0827. Diabetes. 2006. PMID: 17130503 Clinical Trial. - Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.
von Scholten BJ, Reinhard H, Hansen TW, Schalkwijk CG, Stehouwer C, Parving HH, Jacobsen PK, Rossing P. von Scholten BJ, et al. J Diabetes Complications. 2016 Mar;30(2):248-55. doi: 10.1016/j.jdiacomp.2015.11.005. Epub 2015 Nov 6. J Diabetes Complications. 2016. PMID: 26651261 - The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Clinical Trial. - Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ, Lewis JB. Lewis EJ, et al. Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review. - Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Palmer AJ, Valentine WJ, Ray JA. Palmer AJ, et al. Int J Clin Pract. 2007 Oct;61(10):1626-33. doi: 10.1111/j.1742-1241.2007.01343.x. Int J Clin Pract. 2007. PMID: 17877649 Review.
Cited by
- Mechanistic Causes of Reduced Cardiorespiratory Fitness in Type 2 Diabetes.
Abushamat LA, McClatchey PM, Scalzo RL, Schauer I, Huebschmann AG, Nadeau KJ, Liu Z, Regensteiner JG, Reusch JEB. Abushamat LA, et al. J Endocr Soc. 2020 Jun 7;4(7):bvaa063. doi: 10.1210/jendso/bvaa063. eCollection 2020 Jul 1. J Endocr Soc. 2020. PMID: 32666009 Free PMC article. Review. - Vascular Cell Adhesion Molecule 1, Intercellular Adhesion Molecule 1, and Cluster of Differentiation 146 Levels in Patients with Type 2 Diabetes with Complications.
Hocaoglu-Emre FS, Saribal D, Yenmis G, Guvenen G. Hocaoglu-Emre FS, et al. Endocrinol Metab (Seoul). 2017 Mar;32(1):99-105. doi: 10.3803/EnM.2017.32.1.99. Endocrinol Metab (Seoul). 2017. PMID: 28345319 Free PMC article. - Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans.
Szerlip HM, Edwards ML, Williams BJ, Johnson LA, Vintimilla RM, O'Bryant SE. Szerlip HM, et al. J Am Geriatr Soc. 2015 Oct;63(10):2023-8. doi: 10.1111/jgs.13665. Epub 2015 Oct 12. J Am Geriatr Soc. 2015. PMID: 26456700 Free PMC article. - Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.
Pena MJ, Mischak H, Heerspink HJ. Pena MJ, et al. Diabetologia. 2016 Sep;59(9):1819-31. doi: 10.1007/s00125-016-4001-9. Epub 2016 Jun 25. Diabetologia. 2016. PMID: 27344310 Free PMC article. Review. - Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria.
Poulsen CG, Rasmussen DGK, Genovese F, Hansen TW, Nielsen SH, Reinhard H, von Scholten BJ, Jacobsen PK, Parving HH, Karsdal MA, Rossing P, Frimodt-Møller M. Poulsen CG, et al. PLoS One. 2023 Mar 17;18(3):e0283296. doi: 10.1371/journal.pone.0283296. eCollection 2023. PLoS One. 2023. PMID: 36930632 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous